Trial Profile
IGHID 11627 - A Phase I Study to Evaluate the Effects of Vorinostat and HIV-1 Antigen Expanded Specific T Cell Therapy (HXTC) on Persistent HIV-1 Infection in HIV-Infected Individuals Started on Antiretroviral Therapy (The XTRA Study)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 May 2023
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Acronyms XTRA
- 02 Aug 2022 Status changed from active, no longer recruiting to completed.
- 12 Apr 2022 Status changed from recruiting to active, no longer recruiting.
- 18 Feb 2021 Planned End Date changed from 1 Jun 2021 to 1 Jun 2022.